Emergent BioSolutions (EBS) Tops Q2 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.34 --0%
Revenue Growth %: -45.6%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
PHAR, EEFT, INIO, More
Revenue Growth %: -45.6%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
PHAR, EEFT, INIO, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $140.9 million versus the consensus estimate of $174 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rambus Inc. (RMBS) PT Raised to $103 at Susquehanna
- Five Star Bancorp (FSBC) Tops Q3 EPS by 7c
- Bladex (BLX) Reports Q3 EPS of $1.48
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
